Solid Historical Financial Ratios
| SLDB Stock | USD 5.05 0.06 1.17% |
Solid Biosciences is promptly reporting on over 98 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 9.98, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 1.06 will help investors to properly organize and evaluate Solid Biosciences LLC financial condition quickly.
Solid |
About Solid Financial Ratios Analysis
Solid Biosciences LLCFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Solid Biosciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Solid financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Solid Biosciences history.
Solid Biosciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Solid Biosciences LLC stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Solid Biosciences sales, a figure that is much harder to manipulate than other Solid Biosciences LLC multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Solid Biosciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Solid Biosciences LLC current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. At present, Solid Biosciences' PTB Ratio is projected to increase based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 9.98, whereas Free Cash Flow Yield is forecasted to decline to (0.82).
| 2023 | 2024 (projected) | Payables Turnover | 37.68 | 39.56 | Days Of Inventory On Hand | 33.64 | 29.9 |
Solid Biosciences fundamentals Correlations
Click cells to compare fundamentals
Solid Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Solid Biosciences fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 2.24 | 2.98 | 0.9 | 0.22 | 0.97 | 1.01 | |
| Book Value Per Share | 29.8 | 38.15 | 29.25 | 24.87 | 6.36 | 9.98 | |
| Free Cash Flow Yield | (0.54) | (0.15) | (0.42) | (2.21) | (0.78) | (0.82) | |
| Operating Cash Flow Per Share | (34.52) | (16.35) | (10.92) | (11.51) | (4.74) | (4.97) | |
| Capex To Depreciation | 1.55 | 0.23 | 0.43 | 1.25 | 0.59 | 0.56 | |
| Pb Ratio | 2.24 | 2.98 | 0.9 | 0.22 | 0.97 | 1.01 | |
| Free Cash Flow Per Share | (36.15) | (16.61) | (11.1) | (11.86) | (4.81) | (5.05) | |
| Roic | (0.61) | (1.35) | (0.66) | (0.34) | (0.68) | (0.65) | |
| Net Income Per Share | (43.05) | (26.03) | (10.13) | (7.7) | (4.83) | (5.07) | |
| Payables Turnover | 0.4 | 1.2 | 13.16 | 0.74 | 37.68 | 39.56 | |
| Cash Per Share | 31.1 | 44.69 | 29.19 | 25.11 | 6.22 | 5.91 | |
| Pocfratio | (1.93) | (6.96) | (2.4) | (0.47) | (1.3) | (1.36) | |
| Capex To Operating Cash Flow | (0.0473) | (0.0159) | (0.0165) | (0.0308) | (0.0161) | (0.0169) | |
| Pfcf Ratio | (1.85) | (6.85) | (2.36) | (0.45) | (1.28) | (1.34) | |
| Days Payables Outstanding | 920.77 | 304.69 | 27.73 | 490.81 | 9.69 | 9.2 | |
| Income Quality | 0.79 | 0.64 | 1.08 | 1.14 | 0.98 | 0.7 | |
| Roe | (1.44) | (0.68) | (0.35) | (0.31) | (0.76) | (0.72) | |
| Ev To Operating Cash Flow | (1.19) | (4.31) | (0.9) | 0.83 | (0.79) | (0.83) | |
| Pe Ratio | (1.55) | (4.37) | (2.59) | (0.7) | (1.27) | (1.34) | |
| Ev To Free Cash Flow | (1.14) | (4.25) | (0.88) | 0.8 | (0.78) | (0.82) | |
| Earnings Yield | (0.65) | (0.23) | (0.39) | (1.43) | (0.79) | (0.83) | |
| Net Debt To E B I T D A | 0.59 | 1.77 | 1.69 | 1.31 | 0.51 | 0.54 | |
| Current Ratio | 4.72 | 6.49 | 9.43 | 9.76 | 8.94 | 6.18 | |
| Tangible Book Value Per Share | 29.8 | 38.15 | 29.25 | 24.87 | 6.36 | 9.98 | |
| Graham Number | 169.91 | 149.46 | 81.66 | 65.62 | 26.29 | 24.97 | |
| Shareholders Equity Per Share | 29.8 | 38.15 | 29.25 | 24.87 | 6.36 | 3.46 | |
| Debt To Equity | 0.0883 | 0.039 | 0.009908 | 0.13 | 0.21 | 0.22 | |
| Capex Per Share | 1.63 | 0.26 | 0.18 | 0.35 | 0.0762 | 0.0724 | |
| Graham Net Net | 22.38 | 33.4 | 26.23 | 19.4 | 4.28 | 6.74 | |
| Interest Debt Per Share | 2.63 | 1.49 | 0.29 | 3.35 | 1.32 | 1.27 | |
| Debt To Assets | 0.0683 | 0.0301 | 0.008878 | 0.11 | 0.16 | 0.17 | |
| Enterprise Value Over E B I T D A | (0.95) | (2.89) | (1.01) | 0.84 | (0.8) | (0.76) | |
| Short Term Coverage Ratios | (48.24) | (25.65) | (52.02) | (38.2) | (40.52) | (42.55) | |
| Price Earnings Ratio | (1.55) | (4.37) | (2.59) | (0.7) | (1.27) | (1.34) | |
| Price Book Value Ratio | 2.24 | 2.98 | 0.9 | 0.22 | 0.97 | 1.01 | |
| Price Earnings To Growth Ratio | (0.0561) | 0.11 | 0.0424 | 0.0291 | 0.0341 | 0.0358 | |
| Days Of Payables Outstanding | 920.77 | 304.69 | 27.73 | 490.81 | 9.69 | 9.2 | |
| Price To Operating Cash Flows Ratio | (1.93) | (6.96) | (2.4) | (0.47) | (1.3) | (1.36) | |
| Price To Free Cash Flows Ratio | (1.85) | (6.85) | (2.36) | (0.45) | (1.28) | (1.34) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.